Epidemiologic study on gestational trophoblastic diseases in Japan

Objective This study aims to estimate the population-based incidence of gestational trophoblastic diseases (GTDs) and to identify the characteristics of gestational trophoblastic neoplasia (GTN) in Japan. Methods The annual number of GTD and live births from 1974 to 2018 were used to estimate the incidence of GTD. The data of 1,574 GTN cases from 1999 to 2018 were analyzed to identify the characteristics of low-risk GTN, high-risk GTN, placental site trophoblastic tumor (PSTT), and epithelioid trophoblastic tumor (ETT). Results The incidence of hydatidiform mole was 2.02 per 1,000 live births on average which decreased from 1974 to 2008 and increased from 2009 to 2018. The incidence of low-risk GTN, high-risk GTN, PSTT, and ETT was 15.3, 3.5, 0.3, and 0.07 per 100,000 live births, respectively. The estimated incidence of post-molar GTN was 9.8% of molar patients. High-risk GTN was diagnosed more pathologically, had more various kinds of antecedent pregnancies, and had longer intervals after the antecedent pregnancy compared to low-risk GTN. Furthermore, 8.2% of high-risk GTN occurred after the subsequent non-molar pregnancy of hydatidiform mole. The cumulative percentage of developing high-risk GTN after hydatidiform mole reached 89.3% at the 60th month. Conclusion The incidence of hydatidiform mole, low-risk GTN, high-risk GTN was 2.02 per 1,000 live births, 15.3 per 100,000 live births, and 3.5 per 100,000 live births, respectively. High-risk GTN was diagnosed more pathologically and later after the antecedent pregnancy than low-risk GTN. Following molar patients for five years is needed to improve the mortality of malignant GTN.

[1]  R. Berkowitz,et al.  Diagnosis and management of gestational trophoblastic disease: 2021 update , 2021, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[2]  H. Kajiyama,et al.  Short tandem repeat analysis to identify the causative pregnancy of high-risk gestational trophoblastic neoplasia: Molar versus nonmolar pregnancy and its relation to the outcome. , 2021, Placenta.

[3]  F. Kikkawa,et al.  Evaluation of a routine second curettage for hydatidiform mole: a cohort study , 2020, International Journal of Clinical Oncology.

[4]  H. Kajiyama,et al.  The efficacy and toxicity of 4-day chemotherapy with methotrexate, etoposide and actinomycin D in patients with choriocarcinoma and high-risk gestational trophoblastic neoplasia , 2019, International Journal of Clinical Oncology.

[5]  Giri N. K. Rangan,et al.  Committee , 2019, 2019 International Conference on Radar, Antenna, Microwave, Electronics, and Telecommunications (ICRAMET).

[6]  N. Sebire,et al.  Intensified therapies improve survival and identification of novel prognostic factors for placental-site and epithelioid trophoblastic tumours , 2019, British Journal of Cancer.

[7]  T. Kiyono,et al.  Establishment and characterization of cell lines derived from complete hydatidiform mole , 2017, International journal of molecular medicine.

[8]  F. Kikkawa,et al.  Gestational Trophoblastic Neoplasia and Pregnancy Outcome After Routine Second Curettage for Hydatidiform Mole A Retrospective Observational Study. , 2016, The Journal of reproductive medicine.

[9]  N. Sebire,et al.  Intraplacental choriocarcinoma: Systematic review and management guidance. , 2016, Gynecologic oncology.

[10]  A. Mitsuhashi,et al.  Comparison Between Pathological Diagnosis and Cytogenetic Diagnosis by Short Tandem Repeat Polymorphism Analysis of Suspected Molar Pregnancies. , 2016, The Journal of reproductive medicine.

[11]  F. Kikkawa,et al.  High-dose chemotherapy with autologous peripheral blood stem cell transplantation for choriocarcinoma: A case report and literature review. , 2016, Molecular and clinical oncology.

[12]  F. Kikkawa,et al.  Identification of causative pregnancy of gestational trophoblastic neoplasia diagnosed during pregnancy by short tandem repeat analysis , 2014, Gynecologic oncology case reports.

[13]  N. Yanaihara,et al.  [The general rules for clinical and pathological management of trophoblastic diseases--2011, the 3rd edition]. , 2012, Nihon rinsho. Japanese journal of clinical medicine.

[14]  J. V. van Dijck,et al.  Increase in the incidence of gestational trophoblastic disease in The Netherlands. , 2011, Gynecologic oncology.

[15]  J. Lurain.  Gestational trophoblastic disease I: epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole. , 2010, American journal of obstetrics and gynecology.

[16]  N. Wake,et al.  Incidence of postmolar gestational trophoblastic disease in androgenetic moles and the morphological features associated with low risk postmolar gestational trophoblastic disease , 2010, Cancer science.

[17]  E. Kohorn.  Regional centers for trophoblastic disease. , 2007, American journal of obstetrics and gynecology.

[18]  K. Bagshawe.  Trophoblastic reminiscences. , 2006, The Journal of reproductive medicine.

[19]  S. Mizutani,et al.  Survival rates of patients with choriocarcinoma treated with chemotherapy without hysterectomy: effects of anticancer agents on subsequent births. , 2004, Gynecologic oncology.

[20]  D. Fishman,et al.  Treatment of high-risk gestational trophoblastic neoplasia with etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine chemotherapy. , 2003, Gynecologic oncology.

[21]  S. Sasaki.  Management of gestational trophoblastic diseases in Japan--a review. , 2003, Placenta.

[22]  N. Tanaka,et al.  Changes in the incidence of molar pregnancies. A population-based study in Chiba Prefecture and Japan between 1974 and 2000. , 2003, Human reproduction.

[23]  M. Fukunaga.  Immunohistochemical characterization of p57(KIP2) expression in early hydatidiform moles. , 2002, Human pathology.

[24]  FIGO staging for gestational trophoblastic neoplasia 2000. FIGO Oncology Committee. , 2002, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[25]  R. Mclellan,et al.  Gestational trophoblastic disease. , 2001, Obstetrics and gynecology clinics of North America.

[26]  E S Newlands,et al.  EMA/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  K. Bagshawe,et al.  HYDATIDIFORM MOLE IN ENGLAND AND WALES 1973-83 , 1986, The Lancet.

[28]  G. Vooijs,et al.  Epidemiologic Features of Hydatidiform Mole in the Netherlands , 1983, Obstetrics and gynecology.

[29]  N. Sugawara,et al.  [Incidence of hydatidiform mole and aging of mothers (author's transl)]. , 1982, Nihon Sanka Fujinka Gakkai zasshi.